The nicotinic receptor genes

S. Heinemann, J. Boulter, J. Connolly, E. Deneris, Robert Duvoisin, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, A. O'Shea-Greenfield, R. Papke, S. Rogers, J. Patrick

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The causative factor(s) of Alzheimer's disease (AD) are presently unknown. However, it has been shown that the number as well as the fraction of high- to low-affinity nicotine binding sites is altered in patients suffering from this disease. This finding, along with the identification of seven genes which code for nicotinic receptors expressed in the mammalian brain, has led to the idea that one nicotinic receptor subtype may be specifically altered in AD. The present article reviews how, through a molecular genetic approach, a family of genes coding for nicotinic acetylcholine receptor subtypes was uncovered. Also discussed is the use of in situ hybridization to determine the distribution of expression of the mRNA encoding for each receptor subtype and the patch clamp technique to characterize their biophysical properties. Determination of the promoters of these genes, as well as the properties of the expressed receptor subtypes, may make it possible to design new specific nicotinic receptor subtype drugs that will treat not only the symptoms of AD but the progression of the disease process as well.

Original languageEnglish (US)
JournalClinical Neuropharmacology
Volume14
Issue numberSUPPL. 1
StatePublished - 1991
Externally publishedYes

Fingerprint

Nicotinic Receptors
Alzheimer Disease
Genes
Patch-Clamp Techniques
Nicotine
In Situ Hybridization
Disease Progression
Molecular Biology
Binding Sites
Messenger RNA
Brain
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Nicotine receptors

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Heinemann, S., Boulter, J., Connolly, J., Deneris, E., Duvoisin, R., Hartley, M., ... Patrick, J. (1991). The nicotinic receptor genes. Clinical Neuropharmacology, 14(SUPPL. 1).

The nicotinic receptor genes. / Heinemann, S.; Boulter, J.; Connolly, J.; Deneris, E.; Duvoisin, Robert; Hartley, M.; Hermans-Borgmeyer, I.; Hollmann, M.; O'Shea-Greenfield, A.; Papke, R.; Rogers, S.; Patrick, J.

In: Clinical Neuropharmacology, Vol. 14, No. SUPPL. 1, 1991.

Research output: Contribution to journalArticle

Heinemann, S, Boulter, J, Connolly, J, Deneris, E, Duvoisin, R, Hartley, M, Hermans-Borgmeyer, I, Hollmann, M, O'Shea-Greenfield, A, Papke, R, Rogers, S & Patrick, J 1991, 'The nicotinic receptor genes', Clinical Neuropharmacology, vol. 14, no. SUPPL. 1.
Heinemann S, Boulter J, Connolly J, Deneris E, Duvoisin R, Hartley M et al. The nicotinic receptor genes. Clinical Neuropharmacology. 1991;14(SUPPL. 1).
Heinemann, S. ; Boulter, J. ; Connolly, J. ; Deneris, E. ; Duvoisin, Robert ; Hartley, M. ; Hermans-Borgmeyer, I. ; Hollmann, M. ; O'Shea-Greenfield, A. ; Papke, R. ; Rogers, S. ; Patrick, J. / The nicotinic receptor genes. In: Clinical Neuropharmacology. 1991 ; Vol. 14, No. SUPPL. 1.
@article{23818f43fc2f4164802ecabb2f3f09dd,
title = "The nicotinic receptor genes",
abstract = "The causative factor(s) of Alzheimer's disease (AD) are presently unknown. However, it has been shown that the number as well as the fraction of high- to low-affinity nicotine binding sites is altered in patients suffering from this disease. This finding, along with the identification of seven genes which code for nicotinic receptors expressed in the mammalian brain, has led to the idea that one nicotinic receptor subtype may be specifically altered in AD. The present article reviews how, through a molecular genetic approach, a family of genes coding for nicotinic acetylcholine receptor subtypes was uncovered. Also discussed is the use of in situ hybridization to determine the distribution of expression of the mRNA encoding for each receptor subtype and the patch clamp technique to characterize their biophysical properties. Determination of the promoters of these genes, as well as the properties of the expressed receptor subtypes, may make it possible to design new specific nicotinic receptor subtype drugs that will treat not only the symptoms of AD but the progression of the disease process as well.",
keywords = "Alzheimer's disease, Nicotine receptors",
author = "S. Heinemann and J. Boulter and J. Connolly and E. Deneris and Robert Duvoisin and M. Hartley and I. Hermans-Borgmeyer and M. Hollmann and A. O'Shea-Greenfield and R. Papke and S. Rogers and J. Patrick",
year = "1991",
language = "English (US)",
volume = "14",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The nicotinic receptor genes

AU - Heinemann, S.

AU - Boulter, J.

AU - Connolly, J.

AU - Deneris, E.

AU - Duvoisin, Robert

AU - Hartley, M.

AU - Hermans-Borgmeyer, I.

AU - Hollmann, M.

AU - O'Shea-Greenfield, A.

AU - Papke, R.

AU - Rogers, S.

AU - Patrick, J.

PY - 1991

Y1 - 1991

N2 - The causative factor(s) of Alzheimer's disease (AD) are presently unknown. However, it has been shown that the number as well as the fraction of high- to low-affinity nicotine binding sites is altered in patients suffering from this disease. This finding, along with the identification of seven genes which code for nicotinic receptors expressed in the mammalian brain, has led to the idea that one nicotinic receptor subtype may be specifically altered in AD. The present article reviews how, through a molecular genetic approach, a family of genes coding for nicotinic acetylcholine receptor subtypes was uncovered. Also discussed is the use of in situ hybridization to determine the distribution of expression of the mRNA encoding for each receptor subtype and the patch clamp technique to characterize their biophysical properties. Determination of the promoters of these genes, as well as the properties of the expressed receptor subtypes, may make it possible to design new specific nicotinic receptor subtype drugs that will treat not only the symptoms of AD but the progression of the disease process as well.

AB - The causative factor(s) of Alzheimer's disease (AD) are presently unknown. However, it has been shown that the number as well as the fraction of high- to low-affinity nicotine binding sites is altered in patients suffering from this disease. This finding, along with the identification of seven genes which code for nicotinic receptors expressed in the mammalian brain, has led to the idea that one nicotinic receptor subtype may be specifically altered in AD. The present article reviews how, through a molecular genetic approach, a family of genes coding for nicotinic acetylcholine receptor subtypes was uncovered. Also discussed is the use of in situ hybridization to determine the distribution of expression of the mRNA encoding for each receptor subtype and the patch clamp technique to characterize their biophysical properties. Determination of the promoters of these genes, as well as the properties of the expressed receptor subtypes, may make it possible to design new specific nicotinic receptor subtype drugs that will treat not only the symptoms of AD but the progression of the disease process as well.

KW - Alzheimer's disease

KW - Nicotine receptors

UR - http://www.scopus.com/inward/record.url?scp=0025783267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025783267&partnerID=8YFLogxK

M3 - Article

C2 - 1913709

AN - SCOPUS:0025783267

VL - 14

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - SUPPL. 1

ER -